The Markets, Final Presidential Debate, FDA Approves First Treatment For COVID-19 And Intel Tumbles
Carl Quintanilla, Jim Cramer and David Faber explored a number of issues on Wall Street's radar: The second and final presidential debate of the 2020 election - including reaction to President Trump's vaccine timeline, Gilead shares rising after its antiviral remdesivir became the first drug to receive FDA approval for treatment of COVID-19, and Intel shares tumbling after weakness in the chip maker's data center business impacted quarterly results. Also in focus: Apple's new iPhone 12 hitting stores in China and what to expect from sales of the device in the U.S., plus the stock winners and losers to cap what has been a busy week on the earnings front.
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Carl Quintanilla, Jim Cramer and David Faber explored a number of issues on Wall Street's radar: The second and final presidential debate of the 2020 election - including reaction to President Trump's vaccine timeline, Gilead shares rising after its
antiviral remdesivir became the first drug to receive FDA approval for treatment of COVID-19, and Intel shares tumbling after weakness in the chip maker's data center business impacted quarterly results.
Also in focus: Apple's new iPhone 12 hitting stores in China and what to expect from sales of the device in the U.S., plus the stock winners and losers to cap what has been a busy week on the earnings front.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.